Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.32 Million GBP | -13.62% |
| 2022 | 3.84 Million GBP | 990.88% |
| 2021 | 352.84 Thousand GBP | -80.28% |
| 2020 | 1.78 Million GBP | 27.88% |
| 2019 | 1.39 Million GBP | 4.36% |
| 2018 | 1.34 Million GBP | 408.35% |
| 2017 | 263.68 Thousand GBP | 83.5% |
| 2016 | 143.69 Thousand GBP | -41.78% |
| 2015 | 246.83 Thousand GBP | 0.0% |
| 2014 | - GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.09 Million GBP | -6.98% |
| 2024 Q2 | 3.09 Million GBP | 0.0% |
| 2023 Q4 | 3.32 Million GBP | 0.0% |
| 2023 Q2 | 3.59 Million GBP | 0.0% |
| 2023 Q1 | 3.59 Million GBP | -6.63% |
| 2023 Q3 | 3.32 Million GBP | -7.49% |
| 2023 FY | 3.32 Million GBP | -13.62% |
| 2022 Q1 | 963.16 Thousand GBP | 172.97% |
| 2022 Q2 | 963.16 Thousand GBP | 0.0% |
| 2022 Q4 | 3.84 Million GBP | 0.0% |
| 2022 FY | 3.84 Million GBP | 990.88% |
| 2022 Q3 | 3.84 Million GBP | 299.63% |
| 2021 Q1 | 1.8 Million GBP | 0.79% |
| 2021 FY | 352.84 Thousand GBP | -80.28% |
| 2021 Q4 | 352.84 Thousand GBP | 0.0% |
| 2021 Q3 | 352.84 Thousand GBP | -80.43% |
| 2021 Q2 | 1.8 Million GBP | 0.0% |
| 2020 Q3 | 1.78 Million GBP | -6.98% |
| 2020 Q4 | 1.78 Million GBP | 0.0% |
| 2020 Q1 | 1.92 Million GBP | 37.48% |
| 2020 FY | 1.78 Million GBP | 27.88% |
| 2020 Q2 | 1.92 Million GBP | 0.0% |
| 2019 Q3 | 1.39 Million GBP | 10.34% |
| 2019 Q4 | 1.39 Million GBP | 0.0% |
| 2019 Q2 | 1.26 Million GBP | 0.0% |
| 2019 FY | 1.39 Million GBP | 4.36% |
| 2019 Q1 | 1.26 Million GBP | -5.41% |
| 2018 Q1 | 283.25 Thousand GBP | 7.42% |
| 2018 Q4 | 1.34 Million GBP | 0.0% |
| 2018 FY | 1.34 Million GBP | 408.35% |
| 2018 Q3 | 1.34 Million GBP | 352.91% |
| 2018 Q2 | 295.96 Thousand GBP | 4.49% |
| 2017 Q1 | - GBP | -100.0% |
| 2017 FY | 263.68 Thousand GBP | 83.5% |
| 2017 Q2 | 218.1 Thousand GBP | 0.0% |
| 2017 Q3 | 263.68 Thousand GBP | 20.9% |
| 2017 Q4 | 263.68 Thousand GBP | 0.0% |
| 2016 Q4 | 143.69 Thousand GBP | 0.0% |
| 2016 FY | 143.69 Thousand GBP | -41.78% |
| 2016 Q2 | 95.4 Thousand GBP | 0.0% |
| 2015 FY | 246.83 Thousand GBP | 0.0% |
| 2014 FY | - GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.763% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 65.301% |
| SQZ Biotechnologies Company | 50.03 Million USD | 93.355% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.412% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 94.366% |
| Mesoblast Limited | 188.44 Million USD | 98.236% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 13.671% |
| Genus plc | 485 Million USD | 99.314% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 43.093% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -32.132% |
| Marizyme, Inc. | 26.67 Million USD | 87.536% |
| ContraFect Corporation | 32.53 Million USD | 89.779% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 12.503% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -67.813% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 13.135% |
| Intellipharmaceutics International Inc. | 12 Million USD | 72.313% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 71.771% |
| MultiCell Technologies, Inc. | 1617.67 USD | -205435.554% |
| Accustem Sciences Inc. | 1.07 Million USD | -208.077% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.705% |
| EV Biologics, Inc. | 2.11 Million USD | -57.2% |
| Q BioMed Inc. | 8.13 Million USD | 59.118% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.991% |
| Neon Bloom, Inc. | 1.22 Million USD | -171.151% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 35.389% |
| Biomind Labs Inc. | 1.49 Million USD | -121.864% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.638% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 81.933% |
| Skye Bioscience, Inc. | 14.07 Million USD | 76.373% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -65.407% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2239.904% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 64.875% |
| IMV Inc. | 37.93 Million USD | 91.235% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1553.219% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 42.134% |
| GB Sciences, Inc. | 5.41 Million USD | 38.628% |
| Alpha Cognition Inc. | 7.16 Million USD | 53.594% |
| HST Global, Inc. | 593.59 Thousand USD | -460.129% |
| CSL Limited | 18.62 Billion USD | 99.982% |
| Halberd Corporation | 728.71 Thousand USD | -356.265% |
| Enzolytics Inc. | 365.26 Million USD | 99.09% |
| Resverlogix Corp. | 67.39 Million USD | 95.067% |
| Affymax, Inc. | 8.87 Million USD | 62.52% |
| SYBLEU INC | 681.41 Thousand USD | -387.94% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -296.418% |
| argenx SE | 444.95 Million USD | 99.253% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.562% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -93.984% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 72.067% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 9.284% |
| AVAX Technologies, Inc. | 3.99 Million USD | 16.748% |
| Zenith Capital Corp. | 27.56 Thousand USD | -11960.238% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.749% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1293.183% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 10.964% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -388.355% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.199% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 63.229% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -4867.782% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -131.883% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 93.385% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -22.615% |
| BioStem Technologies, Inc. | 15.9 Million USD | 79.095% |
| ONE Bio Corp. | 27.49 Million USD | 87.908% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -615.493% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -12020.027% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -164.049% |
| Agentix Corp. | 2.51 Million USD | -32.436% |
| LadRx Corporation | 2.2 Million USD | -51.095% |
| Cell Source, Inc. | 15.8 Million USD | 78.965% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7338.892% |
| Regen BioPharma, Inc. | 5.45 Million USD | 39.078% |
| Regen BioPharma, Inc. | 5.45 Million USD | 39.078% |
| NovAccess Global Inc. | 7.86 Million USD | 57.703% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 86.564% |
| Itoco Inc. | 1.65 Million USD | -101.124% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -62.066% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 45.034% |
| Kadimastem Ltd | 3.5 Million USD | 5.135% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -688.695% |
| CytoDyn Inc. | 127.89 Million USD | 97.4% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -7854.465% |
| Mobile Lads Corp. | 1.31 Million USD | -153.132% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -112.266% |
| Qrons Inc. | 1.48 Million USD | -123.34% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 69.898% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -311.092% |
| Rebus Holdings, Inc. | 5.24 Million USD | 36.572% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 45.511% |
| International Stem Cell Corporation | 5.27 Million USD | 36.993% |
| Bioxytran, Inc. | 3.24 Million USD | -2.32% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -431.294% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 27.988% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.89% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 85.067% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -64.161% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 39.305% |
| Neutra Corp. | 973.52 Thousand USD | -241.529% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 88.541% |
| PureTech Health plc | 125.58 Million USD | 97.352% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 11.504% |
| IXICO plc | 1.9 Million USD | -74.967% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 83.804% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.782% |
| CSL Limited | 18.62 Billion USD | 99.982% |
| Cellectis S.A. | 249.36 Million USD | 98.667% |